The Duke Medical Scientist Training Program (MSTP) is one of three original MSTPs funded by NIGMS in 1966, and it has been continuously funded since that time. This competing continuation application requests funding for 32 trainees, an increase of one position over the current level of support. The goal of the Duke MSTP is to prepare young physician-scientists for careers in biomedical research and academic medicine by providing comprehensive training in both scientific research and clinical medicine through completion of both the MD and PhD degrees. The program's mission is to provide an intellectual foundation that will allow trainees from diverse backgrounds to become the future thought leaders in biomedical science and academic medicine in the US. To accomplish these goals, the Program is built on a unique medical school curriculum that integrates medical education with original scholarly investigation. The defining feature of the Duke curriculum is that all medical students engage in significant scholarly activity in the third year. As a consequence, the core medical education takes place over three years, rather than four, with the preclinical basic sciences condensed into the first year and core clinical clerkships taught in the second year. This curriculum is therefore ideally suited to MSTP trainees, as it provides comprehensive clinical training prior to PhD training, allowing students to align their research interests with teir long-term clinical interests as well as shortening the time to the dual degree. Over the past 5 years, the Duke MSTP has undergone a number of major changes and improvements after it came under new directorship in 2006: 1) The admissions process was revamped to ensure recruitment of top tier applicants while also addressing the problem of unacceptably high attrition rates;2) Program administration has been modified to ensure adequate oversight of the director and to provide enhanced input from a broader range of outstanding faculty;3) Improved trainee oversight has been incorporated at multiple stages of the program;4) Numerous program activities have been added to ensure adequate program-wide training opportunities and to foster program unity;5) An accelerated rotation structure has been added to allow time for trainees to take Step 1 of the USMLE and to transition to their thesis labs by the middle of first-year of graduate school;6) Activities to ensure that clinical skills are not lost during thePhD years have been added;7) Institutional support has improved dramatically;and 8) Multiple opportunities for trainees to influence their own career development have been incorporated. These new program initiatives have built on the Duke MSTP's tradition of excellent MD-PhD training to substantially improve and revitalize the program, preparing it for growth over the next 5 years to a new steady state of approximately 88 students.

Public Health Relevance

There is a need to train physician-scientists with an excellent foundation in both biomedical research and clinical medicine in order to gain a more detailed understanding of disease. The Duke Medical Scientist Training Program seeks to train MD-PhD candidates in both medicine and science through a unique curriculum that provides students with comprehensive clinical training prior to their PhD training. Through this program, Duke MSTP students will be poised to translate scientific discoveries into therapies for human disease.

National Institute of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
Institutional National Research Service Award (T32)
Project #
Application #
Study Section
National Institute of General Medical Sciences Initial Review Group (BRT)
Program Officer
Preusch, Peter C
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Duke University
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Davis, Erica E; Frangakis, Stephan; Katsanis, Nicholas (2014) Interpreting human genetic variation with in vivo zebrafish assays. Biochim Biophys Acta 1842:1960-1970
Sampson, John H; Choi, Bryan D; Sanchez-Perez, Luis et al. (2014) EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clin Cancer Res 20:972-84
Choi, Bryan D; Suryadevara, Carter M; Gedeon, Patrick C et al. (2014) Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma. J Clin Neurosci 21:189-90
Killela, Patrick J; Pirozzi, Christopher J; Reitman, Zachary J et al. (2014) The genetic landscape of anaplastic astrocytoma. Oncotarget 5:1452-7
Ashton, Jeffrey R; Clark, Darin P; Moding, Everett J et al. (2014) Dual-energy micro-CT functional imaging of primary lung cancer in mice using gold and iodine nanoparticle contrast agents: a validation study. PLoS One 9:e88129
Gedeon, Patrick C; Riccione, Katherine A; Fecci, Peter E et al. (2014) Antibody-based immunotherapy for malignant glioma. Semin Oncol 41:496-510
Richards, Adam J; Staats, Janet; Enzor, Jennifer et al. (2014) Setting objective thresholds for rare event detection in flow cytometry. J Immunol Methods 409:54-61
Pierce, Theodore T; Calabrese, Evan; White, Leonard E et al. (2014) Segmentation of the canine corpus callosum using diffusion-tensor imaging tractography. AJR Am J Roentgenol 202:W19-25
Lopez, G Y; Grant, G A; Fuchs, H E et al. (2014) Clinico-pathological description of three paediatric medulloblastoma cases with MLL2/3 gene mutations. Neuropathol Appl Neurobiol 40:217-20
Tripuraneni, Vinay; Patel, Keyur; Brennan, Todd V et al. (2014) Fulminant herpes simplex viral hepatitis: ultrasound and CT imaging appearance and a review of the imaging literature. Clin Imaging 38:191-4

Showing the most recent 10 out of 148 publications